张宇超,吴铮,王韶屏,柳景华

• 1:首都医科大学附属北京安贞医院冠心病中心

摘要(Abstract)：

慢性完全闭塞（CTO）病变是一类复杂的冠状动脉病变类型，而合并左心室收缩功能不全（LVSD）为CTO病变疾病的管理带来了更大的挑战。由于临床研究大多将这类复杂高危人群排除在外，因此目前对于CTO病变合并LVSD的认识十分有限，并极大限制了规范的临床诊疗。本文围绕CTO病变合并LVSD患者的人群特征、血运重建的临床获益、治疗策略的选择以及优化治疗的途径等进行综述，以期为临床诊疗提供参考。

关键词(KeyWords)： 慢性完全闭塞病变;左心室收缩功能不全;优化药物治疗;冠状动脉旁路移植术;经皮冠状动脉介入治疗

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金项目（81970291）

作者(Author): 张宇超,吴铮,王韶屏,柳景华

参考文献(References)：

• [1] Ybarra LF, Rinfret S, Brilakis ES, et al. Definitions and clinical trial design principles for coronary artery chronic total occlusion therapies:CTO-ARC consensus recommendations[J].Circulation, 2021, 143(5):479-500.
• [2] Galassi AR, Brilakis ES, Boukhris M, et al. Appropriateness of percutaneous revascularization of coronary chronic total occlusions:an overview[J]. Eur Heart J, 2016, 37(35):2692-2700.
• [3] Hoebers LP, Claessen BE, Elias J, et al. Meta-analysis on the impact of percutaneous coronary intervention of chronic total occlusions on left ventricular function and clinical outcome[J].Int J Cardiol, 2015, 187:90-96.
• [4] Megaly M, Saad M, Tajti P, et al. Meta-analysis of the impact of successful chronic total occlusion percutaneous coronary intervention on left ventricular systolic function and reverse remodeling[J]. J Interv Cardiol, 2018, 31(5):562-571.
• [5] Kook H, Yang JH, Cho JY, et al. Differential clinical impact of chronic total occlusion revascularization based on left ventricular systolic function[J]. Clin Res Cardiol, 2021, 110(2):237-248.
• [6] Tian T, Guan C, Gao L, et al. Predictors for adverse outcomes of patients with recanalized chronic total occlusion lesion[J]. Eur J Clin Invest, 2021, 51(2):e13368.
• [7] Pinto G, Fragasso G, Gemma M, et al. Long-term clinical effects of recanalization of chronic coronary total occlusions in patients with left ventricular systolic dysfunction[J]. Catheter Cardiovasc Interv, 2020, 96(4):831-838.
• [8] Roth C, Goliasch G, Aschauer S, et al. Impact of treatment strategies on long-term outcome of CTO patients[J]. Eur J Intern Med, 2020, 77:97-104.
• [9] Guo L, Meng S, Lv H, et al. Long-term outcomes of successful recanalization compared with optimal medical therapy for coronary chronic total occlusions in patients with and without left ventricular systolic dysfunction[J]. Front Cardiovasc Med, 2021, 8:654730.
• [10] Galassi AR, Boukhris M, Toma A, et al. Percutaneous coronary intervention of chronic total occlusions in patients with low left ventricular ejection fraction[J]. JACC Cardiovasc Interv, 2017, 10(21):2158-2170.
• [11] Khariton Y, Airhart S, Salisbury AC, et al. Health status benefits of successful chronic total occlusion revascularization across the spectrum of left ventricular function:insights from the OPEN-CTO registry[J]. JACC Cardiovasc Interv, 2018, 11(22):2276-2283.
• [12] Rha SW, Cha J, Choi SY, et al. Long-term outcomes of percutaneous coronary intervention on chronic total occlusion in patients with low left ventricular ejection fraction[J]. JACC Cardiovasc Interv, 2020, 13(4):S19.
• [13] Liu Y, Liu YH, Chen JY, et al. A simple pre-procedural risk score for contrast-induced nephropathy among patients with chronic total occlusion undergoing percutaneous coronary intervention[J]. Int J Cardiol, 2015, 180:69-71.
• [14] Tajstra M, Pyka L, Gorol J, et al. Impact of chronic total occlusion of the coronary artery on long-term prognosis in patients with ischemic systolic heart failure:insights from the COMMITHF registry[J]. JACC Cardiovasc Interv, 2016, 9(17):1790-1797.
• [15] Ishida K, Martin-Yuste V, Prat S, et al. Prognosis of patients with reduced left ventricular ejection fraction and chronic total occlusion according to treatment applied[J]. Cardiovasc Revasc Med, 2021, 27:22-27.
• [16] Toma A, Stahli BE, Gick M, et al. Comparison of benefi t of successful percutaneous coronary intervention for chronic total occlusion in patients with versus without reduced （≤40%） left ventricular ejection fraction[J]. Am J Cardiol, 2017, 120(10):1780-1786.
• [17] Tajti P, Karmpaliotis D, Alaswad K, et al. Procedural outcomes of percutaneous coronary interventions for chronic total occlusions in patients with low left ventricular ejection fraction:insights from the progress CTO registry[J]. J Am Coll Cardiol, 2019, 73(9):1279.
• [18] Henriques JP, Hoebers LP, Ramunddal T, et al. Percutaneous intervention for concurrent chronic total occlusions in patients with STEMI:the EXPLORE trial[J]. J Am Coll Cardiol,2016, 68(15):1622-1632.
• [19] Mashayekhi K, Nuhrenberg TG, Toma A, et al. A randomized trial to assess regional left ventricular function after stent implantation in chronic total occlusion:the REVASC trial[J].JACC Cardiovasc Interv, 2018, 11(19):1982-1991.
• [20] Li J, Zhang L, Wang Y, et al. Agreement in left ventricular function measured by echocardiography and cardiac magnetic resonance in patients with chronic coronary total occlusion[J].Front Cardiovasc Med, 2021, 8:675087.
• [21] Bondarenko O, Beek AM, Twisk JW, et al. Time c o u r s e of functional recovery after revascularization of hibernating myocardium:a contrast-enhanced cardiovascular magnetic resonance study[J]. Eur Heart J, 2008, 29(16):2000-2005.
• [22] Glaveckaite S, Valeviciene N, Palionis D, et al. Prediction of long-term segmental and global functional recovery of hibernating myocardium after revascularisation based on low dose dobutamine and late gadolinium enhancement cardiovascular magnetic resonance[J].J Cardiovasc Magn Reson, 2014, 16(1):83.
• [23] Werner GS, Martin-Yuste V, Hildick-Smith D, et al.A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions[J]. Eur Heart J, 2018, 39(26):2484-2493.
• [24] Lee SW, Lee PH, Ahn JM, et al. Randomized trial evaluating percutaneous coronary intervention for the treatment of chronic total occlusion[J]. Circulation, 2019, 139(14):1674-1683.
• [25] Park TK, Lee SH, Choi KH, et al. Late survival benefit of percutaneous coronary intervention compared with medical therapy in patients with coronary chronic total occlusion:a10-year follow-up study[J]. J Am Heart Assoc, 2021, 10(6):e019022.
• [26] van Veelen A, Elias J, van Dongen IM, et al. Percutaneous coronary intervention versus medical therapy for chronic total coronary occlusions:a systematic review and meta-analysis of randomised trials[J]. Neth Heart J, 2021, 29(1):30-41.
• [27] Bao J, Kan R, Chen J, et al. Combination pharmacotherapies for cardiac reverse remodeling in heart failure patients with reduced ejection fraction:a systematic review and network metaanalysis of randomized clinical trials[J]. Pharmacol Res,2021, 169:105573.
• [28] Burnett H, Earley A, Voors AA, et al. Thirty years of evidence on the e ffi cacy of drug treatments for chronic heart failure with reduced ejection fraction:a network Metaanalysis[J]. Circ Heart Fail, 2017, 10(1):e003529.
• [29] Xie W, Zheng F, Song X, et al. Renin-angiotensinaldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction:network metaanalysis[J]. Int J Cardiol, 2016, 205:65-71.
• [30] Mc Murray JJV, Solomon SD, Inzucchi SE, et al.Dapaglifl ozin in patients with heart failure and reduced ejection fraction[J]. N Engl J Med, 2019, 381(21):1995-2008.
• [31] Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction[J]. N Engl J Med, 2020, 382(20):1883-1893.
• [32] McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2021,42(36):3599-3726.
• [33] Chao TH, Chen IC, Li YH, et al. Plasma levels of proprotein convertase subtilisin/kexin type 9 are elevated in patients with peripheral artery disease and associated with metabolic disorders and dysfunction in circulating progenitor cells[J]. J Am Heart Assoc, 2016, 5(5):e003497.
• [34] Liu YQ, Li DD, Chai M, et al. Real world effectiveness of PCSK-9 inhibitors combined with statins versus statins-based therapy among patients with very high risk of atherosclerotic cardiovascular disease in China(RWE-PCSK study)[J]. J Geriatr Cardiol, 2021, 18(4):261-270.
• [35] Greene SJ, Butler J, Albert NM, et al. Medical therapy for heart failure with reduced ejection fraction:the CHAMP-HF registry[J]. J Am Coll Cardiol, 2018, 72(4):351-366.
• [36] Velazquez EJ, Lee KL, Deja MA, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction[J].N Engl J Med, 2011, 364(17):1607-1616.
• [37] Velazquez EJ, Lee KL, Jones RH, et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy[J]. N Engl J Med, 2016, 374(16):1511-1520.
• [38] Ybarra LF, Rinfret S. Why and how should we treat chronic total occlusion? Evolution of state-of-the-art methods and future directions[J]. Can J Cardiol, 2020.
• [39] Habib RH, Dimitrova KR, Badour SA, et al. CABG versus PCI:greater benefi t in long-term outcomes with multiple arterial bypass grafting[J]. J Am Coll Cardiol, 2015, 66(13):1417-1427.
• [40] Dong L, Kang YK, An XG. Short-term and mid-term clinical outcomes following hybrid coronary revascularization versus of fpump coronary artery bypass:a meta-analysis[J]. Arq Bras Cardiol, 2018, 110(4):321-330.
• [41] Keulards DCJ, Vlaar PJ, Wijnbergen I, et al. Coronary physiology before and after chronic total occlusion treatment:what does it tell us[J]? Neth Heart J, 2021, 29(1):22-29.
• [42] Karamasis GV, Kalogeropoulos AS, Mohdnazri SR, et al.Serial fractional fl ow reserve measurements post coronary chronic total occlusion percutaneous coronary intervention[J]. Circ Cardiovasc Interv, 2018, 11(11):e006941.
• [43] Werner GS, Yaginuma K. Left ventricular dysfunction in patients with a chronic total coronary occlusion and the benefit from revascularization[J]. Cardiovasc Revasc Med, 2021, 27:28-30.
• [44] Perera D, Clayton T, Petrie MC, et al. Percutaneous revascularization for ischemic ventricular dysfunction:rationale and design of the REVIVED-BCIS2 trial:percutaneous coronary intervention for ischemic cardiomyopathy[J]. JACC Heart Fail, 2018, 6(6):517-526.
• [45] Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization[J]. Eur Heart J, 2019, 40(2):87-165.
• [46] Abouzaki NA, Exaire JE, Guzman LA. Role of percutaneous chronic total occlusion interventions in patients with ischemic c a r d i o m y o p a t h y a n d r e d u c e d l e f t v e n t r i c u l a r e j e c t i o n fraction[J]. Curr Cardiol Rep, 2018, 20(11):124.
• [47] Vitadello T, Kunze KP, Nekolla SG, et al. Hybrid P E T/MR imaging for the prediction of left ventricular recovery after percutaneous revascularisation of coronary chronic total occlusions[J]. Eur J Nucl Med Mol Imaging, 2020, 47(13):3074-3083.
• [48] D’Egidio G, Nichol G, Williams KA, et al. Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation:a substudy of the PARR-2 trial[J]. JACC Cardiovasc Imaging, 2009, 2(9):1060-1068.
• [49] Ling LF, Marwick TH, Flores DR, et al. Identification of therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction:inducible ischemia versus hibernating myocardium[J]. Circ Cardiovasc Imaging,2013, 6(3):363-372.
• [50] Uebleis C, Hellweger S, Laubender RP, et al. The amount of dysfunctional but viable myocardium predicts long-term survival in patients with ischemic cardiomyopathy and left ventricular dysfunction[J]. Int J Cardiovasc Imaging, 2013, 29(7):1645-1653.
• [51] Chi WK, Gong M, Bazoukis G, et al. Impact of coronary artery chronic total occlusion on arrhythmic and mortality outcomes:a systematic review and Meta-analysis[J]. JACC Clin Electrophysiol, 2018, 4(9):1214-1223.
• [52] Nombela-Franco L, Mitroi CD, Fernandez-Lozano I,et al. Ventricular arrhythmias among implantable cardioverterdefi brillator recipients for primary prevention:impact of chronic total coronary occlusion(VACTO Primary Study)[J]. Circ Arrhythm Electrophysiol, 2012, 5(1):147-154.
• [53] Nombela-Franco L, Iannaccone M, Anguera I, et al. Impact of chronic total coronary occlusion on recurrence of ventricular arrhythmias in ischemic secondary prevention implantable cardioverter-defibrillator recipients(VACTO Secondary Study):insights from coronary angiogram and electrogram analysis[J]. JACC Cardiovasc Interv, 2017, 10(9):879-888.
• [54] Behnes M, Mashayekhi K, Kuche P, et al. Prognostic impact of coronary chronic total occlusion on recurrences of ventricular tachyarrhythmias and ICD therapies[J]. Clin Res Cardiol,2021, 110(2):281-291.
• [55]李其勇，杨佼，陶剑虹.血流储备分数结合心脏磁共振评估冠状动脉慢性完全闭塞病变血运重建适应证初探[J].中国介入心脏病学杂志，2020, 28(1):21-25.
• [56] Sachdeva R, Agrawal M, Flynn SE, et al. The myocardium supplied by a chronic total occlusion is a persistently ischemic zone[J]. Catheter Cardiovasc Interv, 2014, 83(1):9-16.
• [57] Danek BA, Basir MB, O’Neill WW, et al. Mechanical circulatory support in chronic total occlusion percutaneous coronary intervention:insights from a multicenter U.S.registry[J]. J Invasive Cardiol, 2018, 30(3):81-87.
• [58] Patel K, Doshi R, Decter D, et al. Trends in the utilization and in-hospital outcomes when using mechanical circulatory support devices for stable chronic total occlusion treated with percutaneous coronary intervention[J]. Eur J Intern Med,2019, 59:e11-e13.
• [59] Ly HQ, Noly PE, Nosair M, et al. When the complex meets the high-risk:mechanical cardiac support devices and percutaneous coronary interventions in severe coronary artery disease[J]. Can J Cardiol, 2020, 36(2):270-279.